NCT07122414招募中1 期
A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Intravesical FL115 Alone or in Combination With BCG in Subjects With Non-Muscle Invasive Bladder Cancer, Including Dose Escalation and Cohort Expansion
Suzhou Forlong Biotechnology Co.,Ltd,11 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2024年8月16日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 80
- 试验地点
- 11
- 主要终点
- MTD
研究概览
简要总结
The study is to evaluate the safety and tolerability of intravesical FL115 alone or in combination with BCG in the patients with NMIBC, and to determine the RP2D of FL115 in combination with BCG.
To evaluate the preliminary efficacy of FL115 alone or in combination with BCG in the treatment of NMIBC.
The study consists of three parts: FL115 monotherapy dose escalation (Phase Ia), FL115 combined with BCG dose escalation (Phase Ib), and FL115 combined with BCG cohort expansion (Phase II).
Each subject will receive FL115 alone or in combination with intravesical BCG, administered over three treatment periods: induction, enhanced induction/maintenance 1, and maintenance 2.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects aged 18 years or older.
- •Histologic confirmation of non-muscle invasive bladder cancer of the transitional cell carcinoma high-grade subtype (mixed histology tumors allowed if transitional cell histology is predominant histology).
- •Histologically confirmed presence of BCG-unresponsive CIS (with or without Ta or T1 disease) or histologically confirmed presence of BCG-unresponsive high-grade Ta or T1 disease.
- •Absence of resectable disease after transurethral resection (TURBT) procedures (residual carcinoma in situ (CIS) acceptable; patients with T1 tumors must undergo repeat resection and biopsy [inclusive of muscularis propria] if initial biopsy did not include muscularis propria). Patients with high-grade Ta and/or T1 disease should have complete resection before study treatment.
- •Subjects refuse or are judged by the investigator not suitable for radical cystectomy.
- •ECOG score 0-
- •Expected survival ≥ 2 years (judged by the investigator).
- •Adequate organ function.
- •Voluntary written informed consent and agree to comply with all protocol-specified procedures and follow-up evaluations.
排除标准
- •1.Prior Anti-Cancer Treatment History:
- •Have previously received IL-2 or IL-15 agonist therapy, including but not limited to rhIL-15 (NCI), ALT-803 (FL-115), and NKTR-214 (Nektar).
- •Have previously undergone any of the following NMIBC-related treatments:
- •Received extensive pelvic radiotherapy (involving >30% of bone marrow) within 2 years prior to the first dose.
- •Received systemic therapy aimed at treating NMIBC (e.g., radiotherapy, chemotherapy, immunosuppressive therapy) within 4 weeks prior to the first dose.
- •Received intravesical instillation aimed at treating NMIBC within 4 weeks prior to the first dose, including intravesical local treatment delivered transurethrally.
- •Underwent TURBT or other surgical procedures targeting bladder lesions within 2 weeks prior to the first dose.
- •Prior therapies and recovery from related toxicities：
- •a) Known or suspected allergy to FL115, its excipients, interleukin-based therapies, or fusion proteins (Grade 3-4), or to BCG/excipients (for Phase Ib/II).
- •b) Systemic immunosuppressive therapy within 4 weeks before first dose, except: ≤10 mg/day prednisone equivalent, local/inhaled/intranasal steroids, adrenal replacement ≤7.5 mg/day prednisone, or single-dose prophylaxis for contrast allergy.
- •c) Prior allogeneic organ or PBSC/bone marrow transplantation. d) Live virus vaccination within 4 weeks prior to first dose. e) Prior ≥ Grade 3 or treatment-discontinuation irAE due to immunotherapy, except controlled hypothyroidism, type 1 diabetes, or limited skin irAEs.
- •f) Unresolved AEs from prior anti-tumor therapy that have not returned to baseline or ≤ Grade 1 (per CTCAE v5.0) prior to first dose, except alopecia, ≤ Grade 2 neuropathy, or controlled hypothyroidism. Other ≤ Grade 2 AEs require PI and sponsor medical review.
- •3.Medical and Surgical History:
- •History or current diagnosis of muscle-invasive (T2-T4), locally advanced (T3/T4, any N), or metastatic bladder cancer.
- •History or evidence of upper urinary tract (kidney, renal pelvis, ureter) or prostatic urethral tumors.
- •Known vesicoureteral reflux or evidence of bladder perforation.
- •Active urinary tract infection.
- •Discontinuation of prior BCG therapy due to severe adverse events such as sepsis, systemic infection requiring treatment, or urinary incontinence (Phase Ib and II applicable).
- •Post-TURBT complications that preclude intravesical instillation, per investigator judgment.
- •Clinically significant polyuria (e.g., 24-hour urine volume >4000 mL).
- •History of other malignancies within 2 years prior to screening that have shown progression or required active treatment.
- •Active or prior autoimmune disease requiring systemic immunosuppressants or corticosteroids.
- •History of severe pulmonary toxicity.
- •History or imaging evidence of active pulmonary TB within 1 year prior to enrollment, or prior TB infection not adequately treated.
- •Uncontrolled pleural, pericardial, or peritoneal effusion deemed clinically significant by the investigator (e.g., requiring repeated drainage >once/month).
- •History of significant cardiovascular disease.
- •Major surgery within 4 weeks prior to signing informed consent.
- •4.Infectious Disease History
- •a) Severe infections within 4 weeks before first dose. b) Any history of confirmed active HBV, HCV, HIV, or active tuberculosis infection.
- •5.Other Conditions
- •Pregnant or breastfeeding women.
- •Known, documented, or suspected substance abuse. Exceptions: Prescribed opioids for pain control or other investigator-approved, medically justified cases (pending sponsor medical lead agreement).
- •Any other conditions deemed by the investigator to render the subject unsuitable for participation.
研究组 & 干预措施
FL115 and BCG
Experimental
干预措施: FL115 (Drug)
FL115 and BCG
Experimental
干预措施: FL115+BCG (Drug)
结局指标
主要结局
MTD
时间窗: up to 15 months
Maximal Tolerance Dose
RP2D
时间窗: up to 15 months
Recommended Phase II Dose
Safety and tolerability
时间窗: through study completion, up to 5 years
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Complete Response
时间窗: 36 months
Assess incidence of complete response of CIS (with or without Ta/T1 papillary disease) patients at any time
Disease-Free Rate
时间窗: 12 months
Assess disease-free rate at 12 months since first study treatment
次要结局
未报告次要终点
研究者
研究点 (11)
Loading locations...
相似试验
招募中
1 期
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2High-risk Non-muscle Invasive Bladder CancerNCT06378242RemeGen Co., Ltd.24
招募中
1 期
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder CancerNon Muscle InvasiveBladder CancerNCT06732531Zhuhai Beihai Biotech Co., Ltd48
已完成
1 期
Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder CancerNon-muscle Invasive Bladder CancerNCT01458847BioCis Pharma Ltd12
招募中
1 期
Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid TumorsSolid TumorsNCT05740215Shandong New Time Pharmaceutical Co., LTD158
已完成
1 期
Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and NeutropeniaAcute Myeloid LeukemiaNCT03333005Basilea Pharmaceutica20